MSD

Merck to Participate in the Leerink Partners Global Biopharma Conference 2024

Retrieved on: 
星期一, 三月 4, 2024
Biotechnology, General Health, Pharmaceutical, Health, MSD, MRK, Merck & Co., Conference

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, is scheduled to participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024, at 12:40 p.m.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, is scheduled to participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024, at 12:40 p.m.
  • ET.

Merck to Participate in the TD Cowen 44th Annual Health Care Conference

Retrieved on: 
星期二, 二月 27, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, MSD, MRK, Conference

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, is scheduled to participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 1:30 p.m. ET.

Key Points: 

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, is scheduled to participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 1:30 p.m. ET.

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Retrieved on: 
星期五, 二月 23, 2024
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, MSD, NSCLC, MRK, Neoplasm, European Commission, Recurrence, European, Lung cancer, Civil service commission, CHMP, Patient, PD-L1, Merck & Co., Pharmaceutical industry

The recommendation is based on results from the Phase 3 KEYNOTE-671 trial, in which neoadjuvant KEYTRUDA plus chemotherapy followed by adjuvant KEYTRUDA as a single agent after surgical resection demonstrated statistically significant and clinically meaningful improvements in overall survival and event-free survival, the study’s dual primary endpoints, versus neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in these patients.

Key Points: 
  • The recommendation is based on results from the Phase 3 KEYNOTE-671 trial, in which neoadjuvant KEYTRUDA plus chemotherapy followed by adjuvant KEYTRUDA as a single agent after surgical resection demonstrated statistically significant and clinically meaningful improvements in overall survival and event-free survival, the study’s dual primary endpoints, versus neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in these patients.
  • Key eligibility criteria for KEYNOTE-671 included: patients with previously untreated and resectable NSCLC at high risk of recurrence (stage II, IIIA, or IIIB [N2] by American Joint Committee on Cancer eighth edition), regardless of tumor PD-L1 expression.
  • The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union (EU), and a final decision is expected in the first half of 2024.
  • “The CHMP’s positive opinion puts us another step closer to helping certain patients in Europe with earlier stages of non-small cell lung cancer, regardless of PD-L1 expression,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories.

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Retrieved on: 
星期二, 二月 20, 2024
Oncology, FDA, Health, General Health, Pharmaceutical, Biotechnology, MSD, Carboplatin, MRK, Society of Gynecologic Oncology, Food, PDUFA, Risk, Cancer, Gynecologic Oncology (journal), Death, Paclitaxel, SGO, Patient, Pharmaceutical industry

The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 21, 2024.

Key Points: 
  • The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 21, 2024.
  • The sBLA is based on data from the Phase 3 NRG-GY018 trial.
  • Health authorities in Israel, Canada, Australia, Singapore and Brazil will review this application as part of Project Orbis.
  • In endometrial cancer, Merck is evaluating KEYTRUDA in the first-line setting for advanced or recurrent disease that is dMMR (KEYNOTE-C93/ENGOT-en15/GOG-3064) and in the adjuvant setting (KEYNOTE-B21/ENGOT-en11/GOG-3053).

Baseimmune Raises $11.3M in Series A funding to Develop Better Vaccines Faster

Retrieved on: 
星期一, 二月 26, 2024
Health Technology, COVID-19, Technology, Finance, Pharmaceutical, Professional Services, Infectious Diseases, Genetics, Artificial Intelligence, Clinical Trials, Biotechnology, Science, Software, Other Science, Research, Health, MSD, Multimedia, Messenger, Coronavirus, Vaccine, African swine fever virus, University, Malaria, Element, Jenner Institute, COVID, University of Oxford, Big data, Deep learning, DNA

View the full release here: https://www.businesswire.com/news/home/20240219023333/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240219023333/en/
    From left to right: Baseimmune co-founders Ariane C. Gomes (Chief Scientific Officer), Phillip Kemlo (Chief Technology Officer), and Joshua Blight (Chief Executive Officer).
  • Photo credit: Baseimmune
    “We’re thrilled to have the support of a top-tier investor syndicate led by MSD Global Health Innovation Fund and IQ Capital.
  • This funding will enable us to accelerate the development of our technology, scale our programs, and expedite the delivery of impactful vaccines against future pathogens,” said Joshua Blight, CEO & Co-Founder, Baseimmune.
  • By using big data and a design algorithm, Baseimmune has been able to shorten the time it takes to develop a vaccine candidate.

Beyond Type 1 Announces New Board Members and Executive Team

Retrieved on: 
星期四, 二月 15, 2024
MSD, Type 1, Diabetes, SAN, Marketing, Yahoo!, 1Life Healthcare, American Heart Association, Education, The Recording Academy, Growth, Empowerment, Sports marketing, Activision Blizzard, Beyond, Sport, ESPN, Diagnosis, Priyanka Chopra, BDT, MGM Resorts International, Management

SAN MATEO, Calif., Feb. 15, 2024 /PRNewswire/ -- Beyond Type 1 today announced three new board members and four new executives to lead the organization as it grows its program, community, and partner network in 2024.

Key Points: 
  • "Their diverse expertise and unwavering dedication to serving people with diabetes will be instrumental in driving our initiatives forward.
  • They each share an important passion and personal connection to the work of Beyond Type 1."
  • The new members of Beyond Type 1's Board of Directors comprise a diverse set of senior leaders across multiple industries who are all united in their commitment to fighting diabetes.
  • Beyond Type 1 also welcomed four accomplished executives to its leadership team , bringing decades of combined expertise across healthcare, technology, marketing, creative, and operations.

Citryll Announces the Appointment of Maarten Kraan as Chief Medical Officer

Retrieved on: 
星期二, 二月 13, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, MSD, Therapy, Roche, Infliximab, Pfizer, AstraZeneca, Senior, Immune-mediated inflammatory diseases, Merck, Schering-Plough, CMO, Neutrophil, Research and development, Adalimumab, Inflammation, Belatacept, Leiden University, Stallergenes Greer, Bristol Myers Squibb, Abatacept, Rheumatoid arthritis, Hidradenitis suppurativa, Merck & Co., Patient, Pierre Fabre, Biology, Development, Pharmaceutical industry

Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer.
  • Prior to that, he held various senior medical and R&D positions at Pierre Fabre S.A., AstraZeneca, Roche and Bristol Myers-Squibb.
  • Dr. Kraan will replace Dr. Patrick Round, who will continue to support the company during the transition period.
  • Notably, Dr. Kraan was also involved in the development of Orencia (abatacept), Remicade (infliximab), Humira (adalimumab) and fostamatinib for rheumatoid arthritis.

SP Plus Stockholders Approve Merger With Metropolis Technologies

Retrieved on: 
星期一, 二月 12, 2024
Slate, MSD, SP, SP Plus Corporation, Plan, Metropolis, Special, Second request, Willkie Farr & Gallagher, DOJ, BDT, Agreement, Sub

CHICAGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- SP Plus Corporation (“SP+”) (NASDAQ: SP) today announced that at its special meeting of stockholders held on February 9, 2024 (the “Special Meeting”), SP+ stockholders voted to approve the previously announced Agreement and Plan of Merger, dated as of October 4, 2023, by and among Metropolis Technologies, Inc. (“Metropolis”), Schwinger Merger Sub Inc., a direct, wholly owned subsidiary of Metropolis (“Merger Sub”) and SP+ (the “Merger Agreement”), pursuant to which Merger Sub will merge with and into SP+ (the “Merger”), with SP+ surviving the Merger as a wholly owned subsidiary of Metropolis.

Key Points: 
  • CHICAGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- SP Plus Corporation (“SP+”) (NASDAQ: SP) today announced that at its special meeting of stockholders held on February 9, 2024 (the “Special Meeting”), SP+ stockholders voted to approve the previously announced Agreement and Plan of Merger, dated as of October 4, 2023, by and among Metropolis Technologies, Inc. (“Metropolis”), Schwinger Merger Sub Inc., a direct, wholly owned subsidiary of Metropolis (“Merger Sub”) and SP+ (the “Merger Agreement”), pursuant to which Merger Sub will merge with and into SP+ (the “Merger”), with SP+ surviving the Merger as a wholly owned subsidiary of Metropolis.
  • Under the terms of the Merger Agreement, SP+ stockholders will be entitled to receive $54.00 per share in cash, without interest and subject to any required tax withholding, at the closing of the Merger.
  • Approval by SP+’s stockholders satisfies one of the conditions necessary for completion of the Merger.
  • SP+ and Metropolis will continue to cooperate fully with the DOJ in its review.

MERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE TO FURTHER ADVANCE ITS ARTIFICIAL INTELLIGENCE CAPABILITIES AND DRIVE INNOVATION IN HEALTHCARE

Retrieved on: 
星期四, 二月 8, 2024
MSD, AI, Machine learning, Patient, Vector Institute, Vector, Artificial intelligence, MRK, Deep learning, Health, Data science, Organization, Pharmaceutical industry

This agreement will allow Merck Canada to gain access to Vector's exceptional research capabilities and expertise in AI and engage with its robust and thriving ecosystem to drive innovation in healthcare.

Key Points: 
  • This agreement will allow Merck Canada to gain access to Vector's exceptional research capabilities and expertise in AI and engage with its robust and thriving ecosystem to drive innovation in healthcare.
  • As such, Merck Canada will have the opportunity to tap into Vector Institute's extensive network of AI researchers, engineers, and startups.
  • "We are excited about the opportunities that our collaboration with the Vector Institute brings to Merck Canada.
  • Together with Vector, Merck's strong commitment to innovation in health will help realize AI capabilities that can be life-changing for patients," said Tony Gaffney, President and CEO, Vector Institute.

Evaxion Announces Closing of $15 Million Public Offering

Retrieved on: 
星期二, 二月 6, 2024
MSD, Security (finance), ADS, GHI, Prospectus, American depositary receipt, Merck, 3rd Floor, Sale, Merck & Co., Form

MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, who became an Evaxion shareholder in December 2023, participated in this offering.

Key Points: 
  • MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, who became an Evaxion shareholder in December 2023, participated in this offering.
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The gross proceeds to the Company from the offering were $15 million before deducting the placement agent's fees and other offering expenses payable by the Company.
  • The offering was made only by means of a prospectus, which is part of the effective registration statement.